logo
Share SHARE
FONT-SIZE Plus   Neg

Madrigal Pharmaceuticals Inc. (MDGL) Has Surged To A New High On Study Results

Madrigal Pharmaceuticals Inc. (MDGL) announced Wednesday morning that its Phase 2 trial of MGL-3196, in patients with biopsy-proven non-alcoholic steatohepatitis, met its primary endpoint.

Madrigal Pharmaceuticals gapped open sharply higher this morning and has spiked to the upside in early trade. Shares are now up 34.42 at $80.72 on above average volume. The stock has soared to a new high for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT